Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics announces the FDA approval of ELEVIDYS, the first gene therapy approved to treat Duchenne muscular dystrophy.

Recent Articles